Postinfectious COVID-19 Catatonia: A Report of Two Cases.
COVID-19 outbreak
SARS-CoV-2
infectious disease
neurobehavioral
neuropsychiatry
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
04
2021
accepted:
28
06
2021
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
13
8
2021
Statut:
epublish
Résumé
Neuropsychiatric symptoms are a common complication of COVID-19, with symptoms documented both during acute COVID-19 infection (parainfectious) and persisting or developing after the resolution of respiratory symptoms (postinfectious). Patients have presented with a variety of symptoms such as anosmia, thrombotic events, seizures, cognitive and attention deficits, new-onset anxiety, depression, psychosis, and rarely catatonia. Etiology appears to be related to disruption of regular neurotransmission and hypoxic injury secondary to systemic inflammation and cytokine storm. Although rare, catatonia and each of its subtypes have now been reported as complications of COVID-19 and therefore should be considered known to occur in both the parainfectious and postinfectious states. Diagnosis of catatonia in the context of COVID-19 should be considered when work-up for more common medical causes of encephalopathy are negative, there is no identifiable psychiatric etiology for catatonia, and there is a positive response to benzodiazepines.
Identifiants
pubmed: 34381391
doi: 10.3389/fpsyt.2021.696347
pmc: PMC8351790
doi:
Types de publication
Case Reports
Langues
eng
Pagination
696347Informations de copyright
Copyright © 2021 Torrico, Kiong, D'Assumpcao, Aisueni, Jaber, Sabetian, Molla, Kuran and Heidari.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
AJNR Am J Neuroradiol. 2017 Jun;38(6):1070-1078
pubmed: 28183838
Lancet Psychiatry. 2019 Jul;6(7):620-630
pubmed: 31196793
Cureus. 2021 Mar 15;13(3):e13891
pubmed: 33880247
Psychosomatics. 2020 Sep - Oct;61(5):556-560
pubmed: 32605766
Pediatr Neurol. 2021 Jan;114:75-76
pubmed: 33246132
Ann Neurol. 2020 Sep;88(3):626-630
pubmed: 32533727
Crit Care Med. 2014 Mar;42(3):e234-41
pubmed: 24275514
World J Psychiatry. 2016 Dec 22;6(4):391-398
pubmed: 28078203
Brain Behav Immun. 2020 Jul;87:179-181
pubmed: 32454137
J Neuroimmunol. 2020 Dec 15;349:577400
pubmed: 33032013
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
J Neurol. 2020 Oct;267(10):2810-2811
pubmed: 32529577
JAMA Psychiatry. 2021 Jun 1;78(6):682-683
pubmed: 33769431
J Acad Consult Liaison Psychiatry. 2021 Mar-Apr;62(2):256-257
pubmed: 33223217
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Seizure. 2020 Oct;81:18-20
pubmed: 32688169
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
BMC Cancer. 2015 Nov 18;15:914
pubmed: 26582328